首页>
外国专利>
ANDROGEN SUPPRESSION, PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND THE CONCEPT OF CONDITIONALLY ENHANCED VULNERABILITY
ANDROGEN SUPPRESSION, PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND THE CONCEPT OF CONDITIONALLY ENHANCED VULNERABILITY
展开▼
机译:雄激素抑制,前列腺特异膜抗原和条件性增强脆弱性的概念
展开▼
页面导航
摘要
著录项
相似文献
摘要
Anti-androgen therapies represent the cornerstone of prostate cancer (PC) treatment. Yet all PC patients ultimately fail efforts to rein in the androgen receptor (AR). This invention is based on the discovery that prostate-specific membrane antigen (PSMA), a highly PC-specific and clinically validated cell surface target, is AR-suppressed and up-regulated in PC as a result of hormonal manipulation. This up-regulation occurs in an unexpected timeframe and it occurs even in the castrate-resistant setting. As a result, hormonal therapy creates a state of conditionally enhanced vulnerability of PC to PSMA-targeted anti-cancer/cytotoxic agents that can be exploited by leveraging anti-AR therapy by the addition of PSMA-targeted agents. We demonstrate this conditionally enhanced vulnerability in a castrate-resistant animal model. The state of conditionally enhanced vulnerability may be relevant for other cancer targets and efforts to screen for them may improve other cancer therapies.
展开▼